Atomoxetine

Brand names: Strattera · Active ingredient: Atomoxetine Hydrochloride

In short: Atomoxetine capsules are indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older. Atomoxetine capsules are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychologic

Forms & strengthsCapsules: 10 mg of atomoxetine (opaque white, opaquewhite) 18 mg of atomoxetine (opaque dark gold, opaque white) 25 mg of atomoxetine (opaque dark blue, opaquewhite) 40 mg of atomoxetine (opaque dark blue, opaque dark blue) 60 mg of atomoxetine (opaque dark …
LabelDr. Reddy's Laboratories Limited
Label updatedNov 13, 2026

What is Atomoxetine used for?

Atomoxetine capsules are indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older.

Atomoxetine capsules are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with ADHD.

âš  Boxed warning (FDA's strongest warning)

All atomoxetine capsules-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes. Families and caregivers should be advised of the need for close observation and communication with the health care provider. Consider stopping atomoxetine capsules in patients who experience emergent suicidal thoughts and behavior

.

Atomoxetine capsules increased the risk of suicidal ideation in pediatric patients aged 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies.

Atomoxetine dosage

Prior to initiating treatment with atomoxetine capsules, screen patients for a personal or family history of bipolar disorder, mania, or hypomania .

Atomoxetine capsules may be taken with or without food. Take atomoxetine capsules whole; do not open the capsules.

Table 1 includes the recommended atomoxetine capsules dosage in adult patients and pediatric patients 6 years of age and older for acute treatment of ADHD.

Table 1: Recommended Dosage of Atomoxetine Capsules for Acute Treatment of ADHD

Age and Body Weight | Starting Dosage | Titration Interval | Target Dosage | Maximum Dosage

Pediatric patients who weigh lessthan 70 kg | 0.5 mg/kg/day | Minimum of 3 days | 1.2 mg/kg/daya,b | 1.4 mg/kg/day or 100 mg/day, whichever is lessa

Pediatric patients who weigh 70 kg or more and adult patients | 40 mg/day | Minimum of 3 days | 80 mg/daya | 100 mg/daya,c

a Administer either as once daily dosage in the morning or as evenly divided twice daily dosage in the morning and late afternoon/early evening.

b No additional benefit has been demonstrated with atomoxetine capsules dosages higher than 1.2 mg/kg/day .

c If a patient has not achieved an optimal response at 80 mg/day after 2 to 4 additional weeks, may increase the dosage to a maximum of 100 mg/day. There is no data that supports increased effectiveness at a dosage higher than 100 mg/day .

The health care provider who elects to use atomoxetine capsules for extended periods should periodically reevaluate the long-term usefulness of atomoxetine capsules for the individual patient.

For patients aged 6 years of age or older with:

Severe hepatic impairment (HI) (Child-Pugh Class C), the recommended initial and target atomoxetine capsules dosage is 25% of recommended dosage in patients with normal hepatic function .

Moderate HI (Child-Pugh Class B), the recommended initial and target atomoxetine capsules dosage is 50% of the recommended dosage in patients with normal hepatic function .

Mild HI (Child-Pugh Class A), the recommended initial and target atomoxetine capsules dosage is the same as those with normal hepatic function.

Consider genetic testing to determine the patient’s CYP2D6 metabolizer status.In patients taking a concomitant strong CYP2D6 inhibitor or who are CYP2D6 poor metabolizers, a longer titration interval of 4 weeks is recommended, if ADHD symptoms fail to improve and the initial atomoxetine capsules dosage is well tolerated. The recommended starting, target, and maximum atomoxetine capsules dosages are the same as outlined in Table 1 .

For other CYP2D6 metabolizer types (ultrarapid, normal, and intermediate), follow the recommended dosage, including the recommended titration interval (minimum of 3 days), as outlined in Table 1 . …

How to take Atomoxetine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Suicide Risk

Patients, their families, and their caregivers should be alerted about the need to monitor patients daily for the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, depression, and suicidal ideation, especially early during atomoxetine capsules treatment and when the dosage is adjusted. Such symptoms should be reported to the patient’s health care provider immediately .

Severe Liver Injury

Patients initiating atomoxetine capsules should be cautioned that severe liver injury may develop. Patients should be instructed to contact their healthcare provider immediately should they develop pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained “flu-like” symptoms . …

Warnings & precautions

Do not take this medicine if: Atomoxetine capsules are contraindicated in patients:

With known hypersensitivity reaction to atomoxetine hydrochloride or other constituents of atomoxetine capsules. Hypersensitivity reactions included anaphylaxis, angioneurotic edema, urticaria, and rash .

Taking, or within 14 days of stopping, a monoamine oxidase inhibitor (MAOI) .

With narrow angle glaucoma. In clinical trials, atomoxetine hydrochloride use was associated with an increased risk of mydriasis.

With pheochromocytoma or a history of pheochromocytoma. Serious reactions, including elevated blood pressure and tachyarrhythmia, have been reported in patients with pheochromocytoma or a history of pheochromocytoma who received atomoxetine capsules.

With severe cardiac or vascular disorders whose condition would be expected to deteriorate if they had a clinically important increase in blood pressure or heart rate (e.g., 15 to 20 mm Hg in blood pressure or 20 beats per minute in heart rate) .

All atomoxetine hydrochloride-treated pediatric patients should be monitored and observed closely for clinical worsening, suicidal thoughts and behavior, and unusual changes in behavior, especially during the initial few months of atomoxetine hydrochloride therapy, or at times of dosage changes, either increases or decreases.

Families and caregivers of atomoxetine hydrochloride-treated pediatric patients should be alerted about the need to monitor patients daily for the emergence of agitation, irritability, unusual changes in behavior, and mental health-related symptoms, as well as the emergence of suicidal thoughts and behavior, and to report such symptoms immediately to a health care provider. …

Atomoxetine side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Atomoxetine hydrochloride was administered to 5,382 pediatric patients 6 years of age and older in clinical ADHD studies (Studies 1, 2, 3, 4, and 5) and 1,007 adults in clinical ADHD studies (Studies 6 and 7) . In the ADHD clinical trials, 2,529 pediatric patients were treated for over 6 months which included 1,625 pediatric patients who were treated for longer than 1 year.

Adverse Reactions in the Clinical Trials of Pediatric Patients 6 Years of Age and Older with ADHD

Discontinuation of Treatment Due to Adverse Reactions in the Clinical Studies of Pediatric Patients 6 Years of Age and Older:

In the acute placebo-controlled studies of pediatric patients 6 years of age and older with ADHD, 3% (48/1,613) of atomoxetine hydrochloride-treated pediatric patients and 1.4% (13/945) of placebo-treated pediatric patients discontinued due to an adverse reaction. Among atomoxetine hydrochloride-treated patients, irritability (0.3%, N=5); somnolence (0.3%, N=5); aggression (0.2%, N=4); nausea (0.2%, N=4); vomiting (0.2%, N=4); abdominal pain (0.2%, N=4); constipation (0.1%, N=2); fatigue (0.1%, N=2); feeling abnormal (0.1%, N=2); and headache (0.1%, N=2) were the reasons for discontinuation reported by more than one patient. …

Drug interactions

See Table 8 for clinically significant drug interactions with atomoxetine capsules and other drugs.

Table 8: Clinically Significant Drug Interactions with Atomoxetine Capsules and Other Drugs

Monoamine OxidaseInhibitors (MAOIs)

Prevention or Management | Atomoxetine capsules are contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue, or in patients whostopped an MAOIwithin 14 days.

Mechanism and Clinical Effect(s) | As with other drugs affecting brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (hyperthermia, rigidity, myoclonus, autonomic instability with fluctuations of vital signs, extreme agitation progressing to delirium/coma) withconcomitant use of atomoxetine capsules and an MAOI. Somecases presented withfeatures resembling neuroleptic malignant syndrome.

Strong CYP2D6Inhibitors

Prevention or Management | With concomitant use of atomoxetine capsules and a strong CYP2D6 inhibitor, increase the titration interval .

Mechanism and Clinical Effect(s) | Atomoxetine is a CYP2D6 substrate. Theconcomitant use of atomoxetine capsules and a strong CYP2D6 inhibitor increases atomoxetine exposure . …

About this medicine

Atomoxetine is a selective norepinephrine reuptake inhibitor. Atomoxetine hydrochloride is the R(-) isomer as determined by x-ray diffraction and its chemical designation is (-)-N-Methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride and its molecular formula is C17H21NO•HCl, which corresponds to a molecular weight of 291.82. The chemical structure is:

Atomoxetine hydrochloride USP is a white to practically white solid, which is sparingly soluble in water. Atomoxetine capsules, USP are intended for oral administration only.

Each atomoxetine capsule contains 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, or 100 mg of atomoxetine (equivalent to 11.4 mg, 20.6 mg, 28.6 mg, 45.7 mg, 68.6 mg, 91.4 mg and 114.3 mg of atomoxetine hydrochloride, respectively). The capsules also contain pregelatinized starch, dimethicone. The capsule shells contain one or more of the following: FD&C Blue No. 2, gelatin, iron oxide red, iron oxide yellow, sodium lauryl sulfate and titanium dioxide. The capsules are imprinted with edible black ink. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 973bdc9b-6421-7e00-e2b6-3cce036d363e. Read the full official label on DailyMed.